| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
No specific biological target is established. (General class: Endogenous Metabolite; Tryptophan derivative).
|
|---|---|
| ln Vitro |
No specific in vitro biological activity data is publicly available for 5-Bromo-DL-tryptophan beyond its classification as an endogenous metabolite and natural product from Aspergillus fumigatus. As a tryptophan analog, it may act as a tryptophan hydroxylase inhibitor or may be incorporated into proteins in place of tryptophan, altering protein function. It could also affect serotonin biosynthesis by competing with tryptophan. However, these potential activities have not been confirmed. It is used primarily as a chemical intermediate and research tool.
|
| ln Vivo |
No in vivo biological activity data is publicly available for 5-Bromo-DL-tryptophan. No animal studies have been reported for the compound as a standalone drug or bioactive molecule. It is utilized as a building block in pharmaceutical development, particularly targeting neurological disorders, and also as a research reagent, but specific in vivo efficacy has not been reported in standard databases.
|
| Enzyme Assay |
No standardized in vitro receptor or enzyme binding assays have been reported for 5-Bromo-DL-tryptophan. For research purposes, potential interactions with tryptophan hydroxylase (TPH1 and TPH2) could be assessed using enzyme activity assays measuring conversion of tryptophan to 5-hydroxytryptophan, monitored by HPLC-fluorescence, with the compound as a competitive inhibitor. Binding to serum albumin may be assessed by fluorescence quenching. However, such studies are not routinely documented.
|
| Cell Assay |
No specific in vitro cell-based protocols are available for 5-Bromo-DL-tryptophan. For exploratory research, the compound could be tested in neuroblastoma cell lines (SH-SY5Y or PC-12) to assess effects on serotonin synthesis and neuronal differentiation. Tryptophan-depleted culture medium can be used to assess rescue or competitive effects. General cytotoxicity could be measured by MTT assays at concentrations ranging from 1-1000 uM, but no published data is available. The compound is widely used as an intermediate in synthetic chemistry rather than a bioactive compound.
|
| Animal Protocol |
No in vivo animal experiments have been reported for 5-Bromo-DL-tryptophan. As a naturally occurring tryptophan derivative and an intermediate for pharmaceutical synthesis, it has not been directly evaluated in animal models. For research into neurological disorders, compounds are generally synthesized using this intermediate, and the final drug candidates are tested in animal models. The intermediate itself is not typically tested in vivo.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for 5-Bromo-DL-tryptophan. By analogy with tryptophan, it would be expected to be absorbed from the gut, cross the blood-brain barrier via the large neutral amino acid transporter (LAT1), and be metabolized by tryptophan-metabolizing enzymes. However, no PK studies are available. The compound has molecular weight 283.12, LogP of 1.89, melting point 264degC (decomposes), and solubility in DMSO. Storage: powder at -20degC, protected from light.
|
| Toxicity/Toxicokinetics |
No toxicology data is publicly available for 5-Bromo-DL-tryptophan. As a brominated aromatic amino acid derivative, it may have potential genotoxicity or cytotoxicity, but specific data is not available. The compound should be handled with standard chemical safety precautions (gloves, lab coat, eye protection). Avoid inhalation and ingestion. It is for research use only, not for human therapeutic or veterinary use. The naturally occurring brominated compound from Aspergillus fumigatus may be produced as a secondary metabolite under specific conditions.
|
| References | |
| Additional Infomation |
5-Bromo-DL-tryptophan is a non-protein α-amino acid formed by replacing the hydrogen atom at the 5-position of the tryptophan indole ring with a bromine atom. It is a bromoamino acid, a tryptophan derivative, a bromoindole, and also a non-protein α-amino acid. It is a zwitterion of 5-bromotryptophan. 5-Bromo-DL-tryptophan has been reported in Aspergillus fumigatus, and relevant data are available. The reference number (RN) given here refers to the (DL)-isomer; for compounds without isomer names, reference number (RN) was not available in January 1991; structure is available from the first source.
5-Bromo-DL-tryptophan is a natural product isolated from Aspergillus fumigatus. It is widely used as a research intermediate in the synthesis of various pharmaceuticals, particularly those targeting neurological disorders. It is also utilized as a building block in organic synthesis, medicinal chemistry, and as an analytical standard for method development. The compound is strictly for laboratory research use only, not intended for human or veterinary use, and is not approved as a drug. |
| Molecular Formula |
C11H11BRN2O2
|
|---|---|
| Molecular Weight |
283.12
|
| Exact Mass |
282
|
| CAS # |
6548-09-0
|
| PubChem CID |
96735
|
| Appearance |
Solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
495.8±45.0 °C at 760 mmHg
|
| Melting Point |
264 °C (dec.)(lit.)
|
| Flash Point |
253.7±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.718
|
| LogP |
1.89
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C=C1Br)C(=CN2)CC(C(=O)O)N
|
| InChi Key |
KZDNJQUJBMDHJW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11BrN2O2/c12-7-1-2-10-8(4-7)6(5-14-10)3-9(13)11(15)16/h1-2,4-5,9,14H,3,13H2,(H,15,16)
|
| Chemical Name |
2-amino-3-(5-bromo-1H-indol-3-yl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5321 mL | 17.6604 mL | 35.3207 mL | |
| 5 mM | 0.7064 mL | 3.5321 mL | 7.0641 mL | |
| 10 mM | 0.3532 mL | 1.7660 mL | 3.5321 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
